Published data suggest Veracyte's Decipher Prostate Biopsy genomic classifier may help guide the use of active surveillance in prostate cancer ...

More careful patient selection for prostate biopsy would reduce health care pollution associated with the procedure, according to study results published in European Urology.In the study ...

Traditionally, a transrectal biopsy was the standard procedure to test for prostate cancer if a prostate-specific antigen blood test was elevated and/or a digital rectal exam was flagged.

Being the cause of death of 1 in 44 people, prostate cancer is known as a silent killed and is the second most common reason for death in men. While there are ways to get prostate cancer checked, it ...

In the US, prostate cancer is the second leading cause of cancer death in men – but experts can’t agree about testing ...

SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer.

A Yale-led study examines the potential environmental benefits of more carefully selecting patients for prostate biopsy in a way that can also spare low-yield and potentially harmful procedures.

The draft guidelines recommend mpMRI to supplement PSA testing to better determine if a biopsy is needed. This saves men from unnecessary invasive procedures and reduces health-system costs.